MUC5AC and neoplasm: In this study, we aimed to validate the group of reported candidate-CCA biomarkers, namely S100A9, MUC5AC, TGF-β1, angiopoietin-2, and the commonly used tumor marker, CA19-9, in the sera of CCA patients compared with healthy people and other GI cancer groups.